Another report described preoperative treatment using the neoadjuvant ALK inhibitor crizotinib for tumor reduction of locally advanced IMT of the bladder, enabling bladder-preserving surgery without recurrence [46]. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.